The study is testing a new treatment called CD19-CAR_Lenti, which involves using the patient’s own immune cells, called T-cells, that are modified in the lab to better recognize and attack cancer cells. This treatment is given through an infusion into the bloodstream. In addition to CD19-CAR_Lenti, the study also uses two other medications, Fludarabine Phosphate and Cyclophosphamide, which are types of chemotherapy drugs that help prepare the body to receive the modified T-cells.

The purpose of the study is to find out how safe and effective the CD19-CAR_Lenti treatment is for these types of cancer. Participants will receive the treatment and be monitored over time to see how their cancer responds. The study will look at how well the treatment works in reducing cancer cells and how long the effects last. Participants will have regular check-ups and tests to track their progress and any side effects they might experience. The study aims to determine the best dose of the treatment and to see if it can help achieve remission, which means the cancer is no longer detectable in the body.

The purpose of the study is to evaluate how effective Axicabtagene Ciloleucel is in treating patients with PMBCL that has either returned after treatment or has not responded to previous treatments. Participants in the study will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will monitor the participants over a period to see how well the treatment works in reducing or eliminating the cancer.

Throughout the study, participants will undergo various assessments, including imaging tests like PET-CT or PET-MRI, to evaluate the response of the cancer to the treatment. These tests help doctors see how the cancer is reacting to the therapy. The study aims to gather information on the treatment’s effectiveness and any potential side effects, contributing to the understanding of how this therapy can be used to help patients with PMBCL.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

The purpose of the study is to understand how the body processes Pembrolizumab when given as a subcutaneous injection and to evaluate its effectiveness and safety in treating these cancers. Participants will receive the treatment in cycles, and researchers will monitor how the drug is absorbed and how well it works in reducing cancer symptoms. The study will also look at the overall response of the cancer to the treatment, as well as any side effects that may occur.

Throughout the study, participants will undergo regular assessments to track their response to the treatment and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using Pembrolizumab in this new form of administration for patients with these specific types of lymphoma.

Participants in the study will receive either tisagenlecleucel or one of the standard care treatments, which may include medications such as fludarabine, ifosfamide, cisplatin, melphalan, oxaliplatin, carmustine, ibrutinib, lenalidomide, gemcitabine hydrochloride, rituximab, cyclophosphamide, bendamustine hydrochloride, tocilizumab, cytarabine, dexamethasone acetate, etoposide, or carboplatin. Some participants may receive a placebo. The purpose of the study is to see if tisagenlecleucel can delay the progression of the disease or improve survival compared to the standard treatments.

The study will involve regular assessments to monitor the participants’ health and the effectiveness of the treatment. These assessments will include medical tests and evaluations to track the progression of the lymphoma and any side effects of the treatments. The study is expected to continue until 2026, with participants being closely monitored throughout the trial period to ensure their safety and to gather comprehensive data on the treatment’s impact.

The purpose of the study is to assess how well Glofitamab works in treating these lymphomas after patients have already received a type of therapy known as CAR T-cell therapy. This therapy involves modifying a patient’s own immune cells to better fight cancer. The study will involve a series of treatments over a period of time, with regular monitoring to see how the cancer responds to the medication. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Participants in the study will receive the treatment through infusions and will be closely monitored by healthcare professionals. The study aims to understand the effectiveness of Glofitamab in improving survival rates and managing the disease. It will also look at how well patients tolerate the treatment and any changes in their quality of life. The study is designed to provide valuable information that could lead to better treatment options for people with these challenging types of lymphoma.

Participants in the study will receive either the combination of acalabrutinib with R-miniCHOP or R-miniCHOP alone. The study is designed for older adults who have not been treated for DLBCL before. The treatment will be administered over a period of time, with regular check-ups to monitor the patient’s health and the progression of the disease. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study aims to provide valuable information on whether the addition of acalabrutinib can improve outcomes for patients with DLBCL. The results will help doctors understand if this combination of treatments is more effective than the standard R-miniCHOP therapy. This research is important for developing better treatment options for patients with this type of lymphoma.